UPDATE 1-Regeneron Pharma expects slowing Eylea sales, shares slip

Feb 9 (Reuters) - Regeneron Pharmaceuticals Inc reported a lower-than-expected profit for the first time in four quarters and forecast slowing sales growth for its blockbuster eye drug this year, sending its shares down 7.8 percent in premarket trading.